each with a MAF of < 0.05. Three pLOF variants met criteria for pathogenicity ( Table   1 1 3 1 and Fig 3) . A novel (i.e., absent from all databases) de novo truncating variant 1 1 4 c.1077C>A (p.Cys359*) with a CADD score of 37 was found in a single HLHS p.Tyr550* had been reported previously in a family with Adams-Oliver syndrome 1 1 8 (AOS) [20] . A novel splicing variant, c.431-1G>A, with a CADD score of 26 was 1 1 9
found in a simplex family with HLHS. This variant was inherited from their father from 1 2 0 whom a DNA sample was unavailable. associations for CHD phenotypes related to NOTCH1 even in the presence of 1 5 0 unrecognized cases within a large control population.
1 5 1
We identified 400 non-coding or coding (missense and synonymous) variants in 1 5 2 NOTCH1 and no pLOF variants (S1 Table) available for analysis imputed with high 1 5 3 quality. Among these 400 variants, none of the coding variants met our pre-specified biobank cohort but were not significantly associated with CHD. Associations the hybrid LVOTO phenotype with two rare intronic variants in NOTCH1 Odds Ratio 19.6, p = 2.44e-6) met the locus-wide threshold for significance ( Fig 4) .
As these two intronic variants appear at similar frequencies within non-European 12.3, p=0.019 and g.chr9:139435649C>T, Odds Ratio 13.9, p = 0.014) ( We detected a likely pathogenic/pLOF mutation in NOTCH1 in 6% of individuals with 1 6 9
HLHS in a Finnish cohort [21] . These variants included a splicing variant and two 1 7 0 truncating variants. These findings suggest that pLOF variants in NOTCH1 may be Further study of missense NOTCH1 variants in a large population-based study of 1 7 4 LVOTO defects did not reveal any significant association between missense variants 1 7 5
and risk for less severe LVOTO-related defects. In the population-based study, 1 7 6 neither common nor rare missense variants in NOTCH1 were significantly 1 7 7 associated with LVOTO defects. Notably, no pLOF variants were identified in the 1 7 8
population-based study cohort, suggesting that such variants are very rare in 1 7 9
putatively healthy population controls. additionally do not appear to be strongly conserved through evolution. Thus a direct 1 9 0 effect of the two variants upon the protein sequence or structure of NOTCH1 is not 1 9 1 clear and will require an experimental approach to determine function which may be 1 9 2 related to transcription or epigenetic regulation. The absence of a significant association of missense variants in NOTCH1 with with LVOTO is lower than previous population estimates of BAV (the most common 2 0 0 type of LVOTO) suggesting some ascertainment errors due to the use of 2 0 1 phenotyping from medical records, perhaps in a combination with a healthy cohort 2 0 2 effect (the individuals in UK Biobank being healthier than the general population). Moreover, as pathogenic NOTCH1 mutations have been found more frequently in 2 0 4 pediatric study cohorts than in adult cohorts, it has been speculated that NOTCH1 subjects. The splice site variant 431-1G>A found in an HLHS proband in this study 2 2 0 was also found in the asymptomatic father indicating reduced penetrance, which is in these are poorly tolerated variants. The truncating p.Tyr550* variant found in one of the HLHS probands studied herein 2 2 7
has been previously reported in a kindred with four affected members with AOS with Based on our analyses in the UK Biobank, which failed to detect a significant 2 3 8 association of missense variants in NOTCH1 with LVOTO-related phenotypes, we 2 3 9
think the four non-synonymous variants are not able to cause disease in isolation.
4 0
However, the inheritance pattern of CHD is in many cases complex, and the vs. controls in three previous LVOTO cohorts [6, 7, 9] . In this study it is seen in 5/49 undiagnosed BAV, which is relatively common. However, recent analyses potential.
5 7
The discovery of the same truncating variant in a family with HLHS and a family with In conclusion, in our study of 49 HLHS individuals, three (6%) had loss of function Rare, highly penetrant LOF variants clearly increase risk for nonsyndromic confirm the pathogenicity of these variants and may serve to elucidate mechanisms 2 9 0 behind reduced penetrance. For genes where causality for cardiac malformations is 2 9 1 well established, our findings may suggest an opportunity to quantify risk conferred 2 9 2 by inherited alleles to increase the known fraction of genetic attributable risk for 2 9 3 CHD. We recruited a cohort of 49 patients with HLHS from Helsinki University Children's 2 9 7
Hospital. Exome sequencing was performed by the University of Washington Center 2 9 8
for Mendelian Genomics Seattle, USA, on DNA samples collected from 37 probands, 2 9 9 7 trios (5 with unaffected or unknown parental phenotypes, and 2 with one affected 3 0 0 parent), and 5 probands with a family history of LVOTO defects. In these latter were removed. RTG-core version 3.3.2 was applied to the raw exome sequence TCACACAGGAAACAGCTATGAGTACCGAGGATGTGGACGAG.
3 2 8
The guidelines of the Declaration of Helsinki were followed and the study was 4, and from self-reported medical history data collected in a questionnaire and codified by a trained nurse for the UK Biobank study (all codes listed in S3 Table) . The LVOTO phenotype was defined as comprising the following individual Table) . Furthermore, of the remaining cases, if the age at diagnosis was >45 for 3 5 1 aortic valve disease and age at surgery was >50 for valve replacement, then the criteria were excluded to minimize the chance of false negatives in the control 3 5 9 population (S3 Table) . Association Testing for NOTCH1 Variants. We performed a primary genetic European and mixed populations. 
